MeiraGTx (MGTX) Projected to Post Quarterly Earnings on Tuesday

MeiraGTx (NASDAQ:MGTX) will likely be posting its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect MeiraGTx to post earnings of ($0.43) per share and revenue of $17.0030 million for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:00 AM ET.

MeiraGTx (NASDAQ:MGTX) last posted its quarterly earnings data on Thursday, March 26th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of ($0.60) by $0.79. MeiraGTx had a negative return on equity of 1,065.47% and a negative net margin of 140.31%.The business had revenue of $75.36 million for the quarter, compared to the consensus estimate of $3.87 million. On average, analysts expect MeiraGTx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

MeiraGTx Stock Up 0.8%

MeiraGTx stock traded up $0.08 during trading on Tuesday, hitting $9.78. The stock had a trading volume of 176,712 shares, compared to its average volume of 602,763. The stock’s 50 day moving average is $8.47 and its two-hundred day moving average is $8.20. MeiraGTx has a 1 year low of $4.55 and a 1 year high of $11.85. The stock has a market cap of $796.54 million, a price-to-earnings ratio of -6.91 and a beta of 1.23.

Insider Buying and Selling at MeiraGTx

In related news, insider Stuart Naylor sold 27,661 shares of the stock in a transaction on Tuesday, April 7th. The stock was sold at an average price of $9.36, for a total value of $258,906.96. Following the sale, the insider owned 668,505 shares in the company, valued at approximately $6,257,206.80. This trade represents a 3.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Alexandria Forbes sold 62,000 shares of the stock in a transaction on Tuesday, March 24th. The stock was sold at an average price of $7.41, for a total value of $459,420.00. Following the completion of the sale, the chief executive officer owned 1,449,695 shares in the company, valued at $10,742,239.95. This trade represents a 4.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 145,661 shares of company stock valued at $1,290,647 in the last 90 days. 7.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On MeiraGTx

Institutional investors and hedge funds have recently made changes to their positions in the business. Deutsche Bank AG raised its position in shares of MeiraGTx by 22.2% in the fourth quarter. Deutsche Bank AG now owns 40,711 shares of the company’s stock worth $324,000 after buying an additional 7,390 shares in the last quarter. Quantinno Capital Management LP purchased a new stake in shares of MeiraGTx in the second quarter worth $319,000. CIBC Bancorp USA Inc. purchased a new stake in shares of MeiraGTx in the third quarter worth $318,000. XTX Topco Ltd raised its position in shares of MeiraGTx by 11.0% in the fourth quarter. XTX Topco Ltd now owns 38,030 shares of the company’s stock worth $302,000 after buying an additional 3,766 shares in the last quarter. Finally, VARCOV Co. purchased a new stake in shares of MeiraGTx in the fourth quarter worth $262,000. Hedge funds and other institutional investors own 67.48% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on MGTX. Bank of America boosted their target price on shares of MeiraGTx from $14.00 to $16.00 and gave the company a “buy” rating in a report on Friday, March 27th. Wall Street Zen raised shares of MeiraGTx from a “sell” rating to a “hold” rating in a report on Sunday, April 5th. Chardan Capital reissued a “buy” rating and set a $35.00 target price on shares of MeiraGTx in a report on Friday, March 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of MeiraGTx in a report on Tuesday, April 21st. Finally, Royal Bank Of Canada boosted their target price on shares of MeiraGTx from $16.00 to $24.00 and gave the company an “outperform” rating in a report on Friday, April 17th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $25.67.

MeiraGTx Company Profile

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.